Details for Patent: 6,899,099

Title:	Method for treating a respiratory disease
Abstract:	The invention provides a novel method of treating respiratory diseases, e.g., pediatric asthma, in a continuing regimen with not more than one daily dose of the drug budesonide using a nebulizer.
Inventor(s):	Andersson; Bertil (Bjarred, SE), Conradsson; Thor-Bjorn (Sodra Sandby, SE), Eriksson; Goran (Dalby, SE)
Assignee:	AstraZeneca AB (Sodertalji, SE)
Filing Date:	Apr 07, 2003
Application Number:	10/409,398
Claims:	1. A method of treating a patient suffering from a respiratory disease, the method comprising administering to the patient a nebulized dose of a budesonide composition in a continuing regimen at a frequency of not more than once per day, wherein the administration is in the evening. 2. The method of claim 1, wherein the frequency is once and only once per day. 3. The method of claim 1, wherein the frequency is once and only once every other day. 4. The method of claim 1, wherein the respiratory disease is selected from the group consisting of an inflammatory airway disease, croup, and bronchopulmonary dysplasia. 5. The method of claim 4, wherein the respiratory disease is asthma. 6. The method of claim 4, wherein the respiratory disease is chronic obstructive pulmonary disease or bronchiolitis. 7. The method of claim 1, wherein the patient is one day to fifteen years old. 8. The method of claim 1, wherein the patient is one month to eight years old. 9. The method of claim 1, wherein the patient is six months to five years old. 10. The method of claim 1, wherein the budesonide composition contains 0.05 mg to 15 mg budesonide. 11. The method of claim 10, wherein the budesonide composition further comprises water and 0.05 mg to 0.15 mg sodium edetate, 8.0 mg to 9.0 mg sodium chloride, 0.15 mg to 0.25 mg polysorbate, 0.25 mg to 0.30 mg anhydrous citric acid, and 0.45 mg to 0.55 mg sodium citrate per 1 ml of water. 12. The method of claim 1, wherein the budesonide composition contains 0.1 mg to 2.0 mg budesonide. 13. The method of claim 1, wherein the budesonide composition contains 0.25 mg to 1.0 mg budesonide. 14. The method of claim 1, wherein the budesonide composition is a suspension. 15. The method of claim 1, wherein the budesonide composition is a solution. 16. The method of claim 1, wherein budesonide is the only active ingredient in the budesonide composition. 17. A kit for treating a respiratory disease, the kit comprising (a) a budesonide suspension in a sealed container, the suspension containing 0.05 mg to 15 mg budesonide and a solvent, and (b) a label indicating administration by nebulization in a continuing regimen at a frequency of not more than once per day. 18. The kit of claim 17, wherein the frequency is once and only once per day. 19. The kit of claim 17, wherein the frequency is once and only once every other day. 20. The kit of claim 17, wherein the respiratory disease is selected from the group consisting of an inflammatory airway disease, croup, and bronchopulmonary dysplasia. 21. The kit of claim 20, wherein the respiratory disease is asthma. 22. The kit of claim 20, wherein the respiratory disease is chronic obstructive pulmonary disease or bronchiolitis. 23. The kit of claim 17, wherein the administration is in the evening. 24. The kit of claim 17, wherein the patient is one day to fifteen years old. 25. The kit of claim 17, wherein the patient is one month to eight years old. 26. The kit of claim 17, wherein the patient is six months to five years old. 27. The kit of claim 17, wherein budesonide is the sole active ingredient in the composition.